U.S. Stem Cell, Inc. USRM
OTC PK
| 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | |
|---|---|---|---|---|---|
| Revenue | -59.14% | -70.73% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -59.14% | -70.73% | -- | -- | -- |
| Cost of Revenue | -54.42% | -49.26% | -- | -- | -- |
| Gross Profit | -60.75% | -75.56% | -- | -- | -- |
| SG&A Expenses | -22.14% | -27.93% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.85% | -28.39% | -- | -- | -- |
| Operating Income | 19.45% | 22.79% | -- | -- | -- |
| Income Before Tax | 13.07% | 9.39% | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.07% | 9.39% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.07% | 9.39% | -- | -- | -- |
| EBIT | 19.45% | 22.79% | -- | -- | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 30.56% | 26.03% | -- | -- | -- |
| Normalized Basic EPS | 38.10% | 20.51% | -- | -- | -- |
| EPS Diluted | 30.56% | 26.03% | -- | -- | -- |
| Normalized Diluted EPS | 38.10% | 20.51% | -- | -- | -- |
| Average Basic Shares Outstanding | 28.33% | 24.28% | -- | -- | -- |
| Average Diluted Shares Outstanding | 28.33% | 24.28% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |